Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharmaceuticals (HOPHF) is a clinical-stage biopharmaceutical company advancing novel therapies for blood cancers and autoimmune diseases through cutting-edge platforms like CAR-T cell technology and bispecific antibodies. This page provides consolidated access to all official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on key initiatives including phase trial progress, strategic collaborations, and intellectual property milestones. Our curated news feed features verified information about HEMO-CAR-T developments, biomarker assay innovations, and therapeutic pipeline advancements.
All content is sourced directly from company filings and press releases, ensuring compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Hemogenyx's progress in developing precision therapies for acute myeloid leukemia and other complex hematological conditions.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced a significant advancement in its CDX bi-specific antibody development for treating relapsed/refractory acute myeloid leukaemia (AML), a subset of acute lymphoblastic leukaemia (ALL), and potentially for conditioning in bone marrow transplantations. The company's scientists have created an improved version of CDX using Lonza's bYlok bispecific pairing technology, which has shown enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.
CEO Dr. Vladislav Sandler highlighted the potential of this development to improve treatment outcomes for patients with often incurable blood cancers. The advancement could accelerate the product candidate's progress towards clinical trials and potentially attract new industry partners interested in co-developing CDX.
Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical company, has been invited to present at the 2024 Chemical and Biological Defense Science & Technology (CBD S&T) Conference in Fort Lauderdale, FL, from December 2-5, 2024. The company will showcase its Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to reprogram innate immune cells to combat viral infections and specific types of cancer.
The presentation, titled 'Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections', will focus on the platform's application in fighting viral threats. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in the biodefense field and engage with experts, potential collaborators, and investors.
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced its participation in the 6th Macrophage-Directed Therapies Summit in Boston, MA, from October 1-3, 2024. The company will present its work on the proprietary Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to program innate immune cells to combat specific cancers and viral threats.
The presentation will focus on using the CBR platform for treating rare cancers. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in myeloid cell therapies and engage with potential collaborators and investors. This event highlights Hemogenyx's commitment to developing innovative treatments for life-threatening diseases, showcasing its state-of-the-art research capabilities in New York City.
Hemogenyx Pharmaceuticals announced the successful passing of all resolutions at its Annual General Meeting held on June 27, 2024. Key resolutions included the adoption of the company's annual accounts, approval of the Directors' Remuneration Report, re-appointment of Sir Marc Feldmann as Director, and re-appointment of PKF Littlejohn LLP as auditors. The voting results showed strong approval from shareholders, with most resolutions receiving over 90% votes in favor. Highlights include a 99.89% approval for the annual accounts and a 99.10% approval for the re-appointment of auditors. The resolutions enable the company to continue its strategic objectives and operational plans effectively.
Hemogenyx Pharmaceuticals has provided an update on its ongoing activities and progress as of June 17, 2024. The company has added a new US medical center to its HEMO-CAR-T clinical trial sites, enhancing its scope and expediting timelines. It is also expanding the HEMO-CAR-T indication to include pediatric AML and ALL. On the Chimeric Bait Receptor (CBR) platform, Hemogenyx is developing multiple CBR constructs for rare cancers and mRNA-based delivery for viral infections. IND-enabling studies for its CDX bispecific antibody are progressing for treating AML and ALL and conditioning in bone marrow transplants. The company is pursuing non-dilutive financing to support these initiatives.
Hemogenyx Pharmaceuticals has announced the posting of its Annual Report and Accounts for the year ending 31 December 2023. The report, along with the Notice of the Annual General Meeting (AGM) and a Form of Proxy, is now available on the company's website. The AGM will take place on 27 June 2024 at 2:00 pm BST at SP Angel Corporate Finance LLP's offices in London. Hemogenyx Pharmaceuticals focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative power of bone marrow transplants.
Shareholders can find more details on the company's investor relations page. The company has its headquarters in London and operates subsidiaries in New York City. The announcement is distributed by RNS, a news service of the London Stock Exchange, and is compliant with regulations established by the Financial Conduct Authority.
FAQ
What is the current stock price of Hemogenyx Pharma (HOPHF)?
What is the market cap of Hemogenyx Pharma (HOPHF)?
